Nucleix

Nucleix develops, manufactures, and markets non-invasive liquid biopsy tests for the early detection and monitoring of various cancers. The company's primary product, Bladder EpiCheck, is a CE-marked and FDA-cleared molecular test used to monitor non-muscle invasive bladder cancer recurrence and upper tract urinary cancer. They are also developing Lung EpiCheck, a blood-based assay designed to detect early-stage lung cancer in high-risk individuals.